Helicobacter pylori is a bacteria that’s responsible for stomach problems such as ulcers and sometimes cancer. The good news, though, is this bug is going away and so are cases of stomach cancer.

Does race enter the equation on who is treated and who isn't treated for cancer? According to a recent study, there are racial differences in how lung cancer is treated.

A new medication that was thought to hold promise for non-Hodgkin lymphoma has been stopped. Pfizer announced it has halted its trial of the investigational compound inotuzumab ozogamicin.

As technology advances, physicians and patients tend to want to use the latest treatment options. These new therapies typically come with a higher price tag. But are they better?

One of the challenges of managing prostate cancer is measuring how aggressive it is. Because a man is diagnosed with prostate cancer doesn’t necessarily mean it needs to be treated.

Imagine this scenario. You’ve just had a colon cancer screening and your doctor tells you, “We’ve found a few pre-malignant neoplasms that may develop into adenocarcinoma.”

People who go through the cancer adventure aren’t sissies – that’s for sure. No, they are the strong ones here to live and laugh another day. Thing is, cancer and its treatments leave their marks.

Even after a cancer is successfully treated, there's still a risk that another cancer may show up at some point down the line. A recent Spanish study looked at the risk of second cancers in breast cancer survivors.

Red meat and processed meats have come under fire lately. Diets loaded with hamburgers, pork chops, bacon, hotdogs and pot roast are associated with heart disease and increased risks of certain cancers. 

Changes to a protein known as EGFR can result in lung cancer. The medication Tarceva (erlotinib) is one of two drugs that target EGFR as a means of treating lung cancer. The use of Tarceva has just been expanded.